Use of complement inhibitors in tissue injury.
Use of complement inhibitors in tissue injury.
复制标题
补体抑制剂在组织损伤中的应用。
DOI：
10.1016/s1471-4914(02)02386-9
复制
发表时间：
2002
影响因子：
13.6
通讯作者：
Quigg,RichardJ
中科院分区：
文献类型：
--
作者：
Quigg,RichardJ
已经积累了大量的信息，涉及补体系统在几个人类疾病过程。虽然这些信息中的一些是间接的，但补体系统的蛋白质抑制剂已经被开发并成功应用于动物实验疾病模型。两种抑制剂，可溶性补体受体1（sCR1）和抗C5单克隆抗体，目前正在研究在各种临床条件下，如系统性红斑狼疮和类风湿性关节炎（RA），目前的治疗变化不大，仍然不令人满意的疾病。RA II期临床试验的初步成功提供了乐观的看法，即补体抑制可能在这些疾病中有用，并成为标准药物治疗的一部分。
A great deal of information has accumulated implicating the complement system in several human disease processes. Although some of this information is circumstantial, protein inhibitors of the complement system have been developed and applied successfully to experimental disease models in animals. Two inhibitors, soluble complement receptor 1 (sCR1) and anti-C5 monoclonal antibody, are now being investigated in a variety of clinical conditions such as systemic lupus erythematosus and rheumatoid arthritis (RA), diseases for which current therapy has changed little and remains unsatisfactory. Preliminary successes in Phase II clinical trials of RA have provided optimism that complement inhibition might prove useful in these diseases and become part of standard medical therapy.